European Journal of Endocrinology (EUR J ENDOCRINOL)

Publisher: European Federation of Endocrine Societies, BioScientifica

Journal description

The journal publishes original research papers, reviews, short communications and case reports within clinical and experimental endocrinology.

Current impact factor: 4.07

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 4.069
2013 Impact Factor 3.686
2012 Impact Factor 3.136
2011 Impact Factor 3.423
2010 Impact Factor 3.482
2009 Impact Factor 3.539
2008 Impact Factor 3.791
2007 Impact Factor 3.239
2006 Impact Factor 3.145
2005 Impact Factor 2.962
2004 Impact Factor 3.14
2003 Impact Factor 2.941
2002 Impact Factor 2.56
2001 Impact Factor 2.133
2000 Impact Factor 2.315
1999 Impact Factor 2.421
1998 Impact Factor 2.101
1997 Impact Factor 1.968
1996 Impact Factor 1.695
1995 Impact Factor 1.234

Impact factor over time

Impact factor

Additional details

5-year impact 3.94
Cited half-life 6.60
Immediacy index 0.73
Eigenfactor 0.02
Article influence 1.19
Website European Journal of Endocrinology website
Other titles European journal of endocrinology
ISSN 0804-4643
OCLC 29970781
Material type Periodical, Internet resource
Document type Journal / Magazine / Newspaper, Internet Resource

Publisher details


  • Pre-print
    • Author cannot archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • In any repository
    • Publisher's version/PDF cannot be used
    • Set statement to accompany deposit (see policy)
    • Publisher last contacted on 18/04/2013
  • Classification

Publications in this journal

  • European Journal of Endocrinology 01/2016; 174(1):85-96. DOI:10.1530/EJE-15-0642

  • European Journal of Endocrinology 12/2015; 173(6):863-872. DOI:10.1530/EJE-15-0839
  • [Show abstract] [Hide abstract]
    ABSTRACT: Context: Some cases of apparently idiopathic GH deficiency (GHD) may be caused by pituitary autoimmunity. Objective: To study the variations from childhood to transition age of pituitary function and pituitary antibodies (APA) in patients with apparently idiopathic GHD. Design: We conducted a longitudinal study. Patients and methods: Pituitary function and APA detection by immunofluorescence were investigated in 24 childhood patients with isolated GHD before starting recombinant GH therapy and after the stopping of this therapy in transition age. Sera of patients positive for APA were processed by double imunofluorescence to identify their pituitary target. Results: At diagnosis, 16 out of 24 patients were APA positive targeting only somatotrophs GH-secreting cells (group 1), while the remaining eight APA negative (group 2). When retested off therapy, 12 out of 16 patients in group 1 persisted APA positive, while the remaining four became negative with recovery of pituitary function. All patients in group 2 persisted APA negative but still showing GHD. Among the 12 patients persisting APA positive, eight with confirmed GHD showed APA still targeting somatotrophs, whereas four showed APA targeting only gonadotrophs, associated with isolated hypogonadotropic hypogonadism (HH). Conclusions: Patients with APA at middle but not at high titer in childhood age may show a remission of autoimmune GHD in childhood, after GH replacement therapy. Since pituitary antibodies may shift their target in transition period, an early characterization of APA by double imunofluorescence is advisable in APA positive GHD patients showing delayed puberty, to allow an early diagnosis and an appropriate therapy, thus preventing the progression toward HH.
    European Journal of Endocrinology 11/2015; DOI:10.1530/EJE-15-0766
  • [Show abstract] [Hide abstract]
    ABSTRACT: Context and objective: The role of cabergoline in Cushing's disease (CD) remains controversial. The experience is limited to case reports and few open studies that report the effects determined after ≥1 month of treatment. In prolactinomas and dopamine-responsive GH-secreting tumours, effects of cabergoline are seen within days or weeks. Here, we searched for short-term effects of cabergoline in CD. Design: Twenty patients (19 naïve and one recurrent) were included in a prospective study. Cabergoline was administered in increasing doses of 0.5-5 mg/week over 6 weeks. Methods: Urinary free cortisol (UFC) 24 h, morning cortisol and ACTH, and salivary cortisol at 0800, 1600 and 2300 h were determined once weekly throughout. Diurnal curves (six samples) of serum cortisol were measured at start and end. Results: At study end, the median cabergoline dose was 5 mg, range 2.5-5 mg/week. The prolactin levels, markers of compliance, were suppressed in all patients. During the treatment, hypercortisolism varied, gradual and dose-dependent reductions were not seen. Five patients had a >50% decrease of UFC, three had a >50% rise of UFC. Salivary cortisol at 2300 h showed a congruent >50% change with UFC in two of the five cases with decreased UFC, and in one of the three cases with increased UFC. One patient with decreases in both UFC and 2300 h salivary cortisol also had a reduction in diurnal serum cortisol during the course of the study. Conclusions: Cabergoline seems to be of little value in the management of CD. Only one patient had a response-like pattern. Given the known variability of disease activity in CD, this might represent a chance finding.
    European Journal of Endocrinology 11/2015; 174(1):17-24. DOI:10.1530/EJE-15-0807
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Thyroid disorders are common in women of reproductive age, but the exact burden of disease before, during and after a pregnancy is not clear. We describe the prevalence of thyroid disease in women enrolled in the Danish National Birth Cohort (DNBC) and investigate some of its risk factors. Design: Population-based study within the DNBC which included 101,032 pregnancies (1997-2003). Methods: We studied women enrolled in the DNBC who gave birth to a live-born child. Information on maternal thyroid disease (hyperthyroidism, hypothyroidism, benign goiter/nodules, thyroid cancer, other) before, during and up to 5 years after the woman's first pregnancy in the cohort was obtained from self-report (telephone interview median gestational week 17) and from nationwide registers on hospital diagnosis/thyroid surgery (from 1977) and prescriptions of thyroid drugs (from 1995). Results: Among 77,445 women studied; 3,018 (3.9%) were identified with onset of thyroid disease before (2.0%), during (0.1%) or in the 5-year period after the pregnancy (1.8%). During the pregnancy, 153 (0.2%) women received antithyroid drugs and 365 (0.5%) received thyroid hormone for hypothyroidism (83 after previous hyperthyroidism, 42 after previous surgery for benign goiter/nodules or thyroid cancer). Significant risk factors for maternal thyroid disease were age, parity, origin, iodine intake, smoking, alcohol, and BMI. Conclusions: Around 4% of Danish pregnant women had either a history of thyroid disease, thyroid disease in the pregnancy or were first time diagnosed with thyroid disease in the years following a pregnancy. The spectrum of thyroid disease was influenced by demographic and environmental factors.
    European Journal of Endocrinology 11/2015; DOI:10.1530/EJE-15-0816
  • [Show abstract] [Hide abstract]
    ABSTRACT: Context: Somatic mutations in the ubiquitin-specific peptidase USP8 gene were recently detected in one to two-third(s) of corticotroph adenomas of Cushing's disease (CD). These mutations may lead to the deubiquitination of EGFR, thereby increasing EGFR signaling, which has been implicated in ACTH hypersecretion. Objective: Our objective was to determine the impact of USP8 mutations on the clinicopathological features of CD. Subjects and methods: USP8 mutations as well as clinicopathological characteristics were examined in 60 corticotroph adenomas including 15 Crooke's cell adenomas (CCAs), a rare histological variant presenting with generally aggressive behavior, using qRT-PCR and/or immunohistochemistry. Results: USP8 mutations were exclusively detected in women, except for one case, with a prevalence of 42.2% in non-CCA and 13.3% in CCA (overall 35%). Clinically well-behaved presentations including microadenoma and curative resection were more common in mutated cases. The expression of EGFR was not associated with the mutation status. In contrast, mutated tumors expressed significantly higher levels of POMC, SSTR5, and MGMT. Conclusions: Microadenomas that strongly express POMC were common among mutated tumors, which may lead to the mechanisms by which very small adenomas secrete excess ACTH to present overt CD. While USP8 mutations were less likely to enhance tumorous ACTH hypersecretion via EGFR-mediated activation, the presence of USP8 mutations may predict favorable responses to the somatostatin analog pasireotide, which exhibits high affinity for SSTR5. In contrast, non-mutated aggressive tumors such as CCA may respond better to the alkylating agent temozolomide because of their significantly weak expression of MGMT.
    European Journal of Endocrinology 11/2015; DOI:10.1530/EJE-15-0689
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To examine whether omental (OM) and subcutaneous (SC) adipocyte size populations in women relate to visceral obesity, cardiometabolic risk factors and adipocyte lipolysis independent of total adiposity. Design and methods: OM and SC fat samples were obtained during gynecological surgery in 60 women [mean age: 46.1±5.9 years; mean BMI: 27.1±4.5 kg/m2 (range: 20.3-41.1 kg/m2)]. Fresh samples were treated with osmium tetroxide and were analyzed with a Multisizer Coulter. Cell size distributions were computed for each sample with exponential and Gaussian function fits. Results: Computed tomography-measured visceral fat accumulation was the best predictor of larger cell populations as well as the percentage of small cells in both OM and SC fat (p<0.0000 for all). Accordingly, women with visceral obesity had larger cells in the main population and higher proportion of small adipocytes independent of total adiposity (p≤0.05). Using linear regression analysis, we found that women characterized by larger-than-predicted adipocytes in either OM or SC adipose tissue presented higher visceral adipose tissue area, increased percentage of small cells and HOMAir index as well as higher OM adipocyte isoproterenol-, forskolin- and dibutyryl cAMP- stimulated lipolysis compared to women with smaller-than-predicted adipocytes, independent of total adiposity (p≤0.05). Conclusion: Excess visceral adipose tissue accumulation is a strong marker of both adipocyte hypertrophy and increased number of small cells in either fat compartment, which relates to higher insulin resistance index and lipolytic response, independent of total adiposity.
    European Journal of Endocrinology 11/2015; DOI:10.1530/EJE-15-0822
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Osteopontin (OPN) is a sialoprotein implicated in different immunity and metabolic pathways. As capable of activating dendritic cells and inducing Th1-Th17-mediated tissue damage, OPN plays a significant role in the development/progression of several autoimmune diseases; interestingly, it was also shown to participate in the acute pancreatic islets response to experimentally-induced diabetes in NOD mice. Furthermore, OPN promotes adipose tissue dysfunction, systemic inflammation and insulin resistance. Aims of this study were to evaluate circulating OPN levels in adult patients with type 1 diabetes mellitus (T1DM) compared to non-diabetic subjects and to unravel clinical and biochemical correlates of OPN concentration. Design: Case-control study. Methods: We enrolled 54 consecutive T1DM patients referred to our diabetes outpatients clinic at Sapienza University of Rome, and 52 healthy sex and age-comparable controls. Study population underwent clinical evaluation, blood sampling for biochemistry and complete screening for diabetes complications. Serum OPN levels were measured by MILLIPLEX Multiplex Assays Luminex®. Results: T1DM patients had significantly higher serum OPN levels than controls (17.2±12.9 vs 10.5±11.6 mg/ml,p=0.009). OPN levels correlated with T1DM, higher blood pressure, BMI, creatinine, γ-GT, ALP and lower HDL; the association between high OPN levels and T1DM was independent from all confounders. No correlation was shown between OPN and HbA1c, C-peptide, insulin requirement, comedications and diabetes duration. Conclusions: This study demonstrates for the first time in a case-control study that adults with T1DM have increased serum OPN levels and higher OPN concentrations are associated with an unfavorable metabolic profile in these patients.
    European Journal of Endocrinology 11/2015; DOI:10.1530/EJE-15-0791
  • [Show abstract] [Hide abstract]
    ABSTRACT: In order to gain further knowledge of the structure of ZnT8 epitopes, we studied the role of amino acid at position 325 in the antigen and its dimeric conformation for ZnT8A recognition. For this purpose, several ZnT8 C-terminal domain variants were designed: monomer carrying Arg325 or Trp325, homo-dimers ZnT8-Arg-Arg325 and ZnT8-Trp-Trp325 and hetero-dimer ZnT8-Arg-Trp325. Two groups of Argentinian diabetic patients were subjected to analysis with [35S]-ZnT8 variants by Radioligand Binding Assay (RBA): 1) 100 new-onset, insulin dependent, type 1 diabetic patients and 2) 282 slowly progressing to insulin requirement, non-obese adult-onset diabetic patients. In addition, 50 type 1 diabetic patients and 100 normal control sera provided by the American Diabetes Association (ADA) were evaluated in order to calculate the sensitivity and specificity of ZnT8A assays for each antigenic variant. Other routine beta-cell autoantibodies were also tested by RBA. Among 100 Argentinian type 1 diabetic patients, 65 were ZnT8A+. Out of them, 8 patients recognized all recombinant forms of ZnT8 and most patients (56) reacted against the heterodimer. Additionally, out of 282 non-obese adult-onset diabetic patients 46 were ZnT8A+, whereas 29 patients recognized only dimers. Besides, exclusive reactivity against ZnT8A was found in 9.0% for type 1 DM and 10.3% for non-obese adult-onset diabetic patients. Significantly higher signal values in RBA were obtained with the heterodimeric variant. An increased detection of humoral autoimmunity was found in both groups when ZnT8A was employed in combination with the other beta-cell autoantibodies. The inclusion of homodimeric immunoreactive peptides revealed the existence of quaternary structure-defined epitopes probably resembling the actual state of the autoantigen in vivo. Finally, the differential profiles of ZnT8A exhibited by type 1 and non-obese adult-onset diabetic patients suggest the different nature of autoimmune processes underling both pathologies.
    European Journal of Endocrinology 11/2015; DOI:10.1530/EJE-15-0681
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To evaluate adrenal crises after the start of treatment up to the age of six years in children with classic congenital adrenal hyperplasia (CAH) Design: Analysis of data extracted from a population-based prospective long-term follow-up study of children detected in neonatal screening. Methods: Data of 102 Bavarian children with classic CAH due to 21-hydroxylase deficiency were analyzed, using parental questionnaires and medical reports. Parent-reported hospital admissions of children diagnosed with acute health impairment were included in the analysis if salt loss (hyponatremia) or hypoglycemia was documented in the discharge summary. Results: 74 children (72.5%) had no report of hospital admissions with salt loss or hypoglycemia during the observational period. However, for 27.5% of the children, 22 salt-wasting crises (7 of these also with low blood glucose) and 16 hypoglycemic episodes without salt loss were reported. Furthermore, the cumulative incidence for seizures was elevated; 13 children experienced seizures during hyponatremia or hypoglycemia. Most adrenal crises were triggered by infections, often with inappropriate emergency management, but in 11 cases hypoglycemia occurred unexpectedly, without evidence of severe illness and without any management errors. Frequency of adrenal crises was 6.5 per 100 patient years (95% - CI: 4.6-8.8). Conclusions: Crisis prevention remains a permanent challenge for families and physicians caring for children with classic CAH. Expert care and compliance with emergency recommendations are crucial. Further research on the interactions between glucocorticoid deficiency, adrenomedullary dysfunction, and glucose metabolism is necessary for the prevention of hypoglycemia, especially in young CAH patients.
    European Journal of Endocrinology 11/2015; DOI:10.1530/EJE-15-0775
  • [Show abstract] [Hide abstract]
    ABSTRACT: Papillary craniopharyngioma is an intracranial tumor that results in high levels of morbidity. We recently demonstrated that the vast majority of these tumors harbor the oncogenic BRAF V600E mutation. The pathologic diagnosis of papillary craniopharyngioma can now be confirmed using mutation specific immunohistochemistry and targeted genetic testing. Treatment with targeted agents is now also a possibility in select situations. We recently reported a patient with a multiply recurrent papillary craniopharyngioma in whom targeting both BRAF and MEK resulted in a dramatic therapeutic response with a marked anti-tumor immune response. This work shows that activation of the MAPK pathway is the likely principal oncogenic driver of these tumors. We will now investigate the efficacy of this approach in a multicenter phase II clinical trial. Post-treatment resection samples will be monitored for the emergence of resistance mechanisms. Further advances in the non-invasive diagnosis of papillary craniopharyngioma by radiologic criteria and by cell-free DNA testing could someday allow neo-adjuvant therapy for this disease in select patient populations.
    European Journal of Endocrinology 11/2015; DOI:10.1530/EJE-15-0957

  • European Journal of Endocrinology 11/2015; 173(5):693-702. DOI:10.1530/EJE-15-0500
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Gestational diabetes (GDM) is defined as a glucose intolerance resulting in hyperglycaemia of variable severity with onset during pregnancy. This review aims to revisit the pathogenesis and aetiology of GDM in order to better understand its clinical presentation and outcomes. During normal pregnancy, insulin sensitivity declines with advancing gestation. These modifications are due to placental factors, progesterone, and estrogen. In a physiological situation, a compensatory increase in insulin secretion maintains a normal glucose homeostasis. GDM occurs if pancreatic beta-cells are unable to face the increased insulin demand during pregnancy. GDM is most commonly a forerunner of type 2 diabetes (T2D) - the most prevalent form of diabetes. These women share similar characteristics with predisposed subjects to T2D: insulin resistance before and after pregnancy, and carry more T2D risk alleles. Auto-immune and monogenic diabetes are more rare aetiologies of GDM. Adverse pregnancy outcomes of GDM are mainly related to macrosomia caused by foetal hyperinsulinism in response to high glucose levels coming from maternal hyperglycaemia. Screening recommendations and diagnosis criteria of GDM have been recently updated. High risk patients should be screened as early as possible using fasting plasma glucose, and if normal, at 24-28 weeks of gestation using 75g Oral Glucose Tolerance Test (OGTT). The treatment of GDM is based on education with trained nurses and dieticians, and if necessary insulin therapy.
    European Journal of Endocrinology 10/2015; DOI:10.1530/EJE-15-0378
  • [Show abstract] [Hide abstract]
    ABSTRACT: Methods: Patients with the diagnosis of DTC who were ≤18 years of age and had no signs of persistent disease at the time of 131I treatment were included. Forty eight patients were treated after rhTSH (rhTSH group) and 82 after L-thyroxin withdrawal (THW group). The median time of follow-up after therapy was 67 months, and was longer in the THW group (99 vs. 43 months, p < 0.05). Results: On the day of 131I administration, all but one patient had TSH levels above 25 µIU/ml. Peak TSH concentration was significantly higher in the rhTSH group (152 µIU/ml vs. 91 µIU/ml). Similarly, the thyroglobulin concentration was higher in the rhTSH group (9.7 ng/ml vs. 1.8 ng/ml). No side effects requiring medical intervention were recorded after rhTSH administration. Evaluation of disease outcomes during TSH stimulation (6 to 18 months after 131I treatment) revealed equal rates of thyroid ablation (71%) in both groups. During subsequent follow-up, five patients showed recurrence (p > 0.05). Conclusions: In children/adolescents, rhTSH-aided adjuvant radioiodine treatment is associated with rates of remnant ablation and short-term recurrence similar to THW. As this preparation has several advantages over THW, rhTSH may become the preferred method of TSH stimulation once studies of long-term outcomes show non-inferiority to THW in this age group.
    European Journal of Endocrinology 09/2015; DOI:10.1530/EJE-15-0562